IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q2 results. We believe more positive clinical data and progress in 2025/26 to be strong catalysts for stock. Raising P/T to $4.75."
Rhea-AI Summary
IGC Pharma (NYSE American: IGC) announced that Ascendiant Capital Markets issued an updated coverage report on December 10, 2025, following IGC's Q2 results. Ascendiant raised its price target to $4.75 and said more positive clinical data and program progress in 2025/26 could act as catalysts for the stock.
The company clarified that analyst reports reflect the analysts' views, that IGC is not responsible for analysts' content or timelines, and provided a link to obtain the full Ascendiant report.
Positive
- Price target raised to $4.75 by Ascendiant Capital Markets
- Analyst cited positive clinical data/progress in 2025/26 as potential stock catalysts
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus 1 Up
IGC was up 2.48% pre-article while peers were mixed: ESLA up 3.99%, LSB down 20.62%, CASI down 7.87%. KLTO appeared in momentum scans, but there is no broad, synchronized sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 09 | Clinical enrollment update | Positive | +2.5% | Reported 65% enrollment in Phase 2 CALMA Alzheimer’s agitation trial. |
| Dec 02 | Educational initiative | Positive | -2.9% | Announced publication of caregiver-focused Alzheimer’s disease book. |
| Nov 25 | AI platform update | Positive | -0.4% | Detailed MINT-AD AI model to analyze Alzheimer’s risk factors and trends. |
| Nov 17 | Earnings and operations | Negative | -5.0% | Q2 FY2026 report with revenue decline and net loss despite trial progress. |
| Nov 13 | Patent grant | Positive | -2.7% | USPTO granted patent covering IGC-AD1 composition for CNS disorders. |
Recent positive operational and IP updates often saw muted or negative price reactions, with only the latest CALMA enrollment milestone aligning positively.
Over the last month, IGC has reported multiple advances around Alzheimer’s programs. On Nov 17, Q2 FY2026 results showed higher R&D and a net loss, followed by AI-platform and caregiver-book updates in late November and early December. The Dec 9 CALMA Phase 2 enrollment at 65% drew a modest gain of 2.48%. Today’s analyst coverage centers on Q2 results and expectations for future clinical progress rather than new trial data.
Regulatory & Risk Context
An active S-3/A resale registration dated Dec 3, 2025 covers up to 978,235 existing and option-related shares for selling stockholders. The company will not receive proceeds from these resales but will bear registration expenses.
Market Pulse Summary
This announcement highlights external analyst coverage referencing IGC’s Q2 results and its Alzheimer’s-focused pipeline, with a raised price target of $4.75. It follows recent milestones such as the CALMA Phase 2 trial reaching 65% enrollment and earlier AI- and IP-related updates. Investors monitoring this story typically focus on continued clinical progress, upcoming data, regulatory filings, and how capital needs and registration statements intersect with trial execution.
Key Terms
artificial intelligence technical
alzheimer's disease medical
AI-generated analysis. Not financial advice.
POTOMAC, MD / ACCESS Newswire / December 10, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company leveraging Artificial Intelligence (AI) to develop innovative treatments for Alzheimer's disease, today announced that Ascendiant Capital Markets has issued a coverage report entitled: "Reports Q2 results. We believe more positive clinical data and progress in 2025/26 to be strong catalysts for stock. Raising P/T to
All reports on IGC Pharma prepared by analysts represent the views of those analysts and are not necessarily those of IGC Pharma. IGC is not responsible for the content, accuracy, or timelines provided by analysts. By referring to these analysts or distributing their opinions, IGC does not in any way commit itself to the validity of such information, conclusions, or recommendations.
A copy of the updated report can be obtained directly from Ascendiant Capital Markets: LINK
About IGC Pharma (dba IGC):
IGC Pharma (NYSE American:IGC) is a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's and metabolic disorders. Our lead asset, IGC-AD1, is a cannabinoid-based therapy currently in a Phase 2 trial (CALMA) for agitation in Alzheimer's dementia. Our pipeline includes TGR-63, targeting amyloid plaques, and early-stage programs focused on neurodegeneration, tau proteins, and metabolic dysfunctions. We integrate AI to accelerate drug discovery, optimize clinical trials, and enhance patient targeting. With a complete patent portfolio and a commitment to innovation, IGC Pharma is advancing breakthrough therapies.
Forward-Looking Statements:
This press release contains forward-looking statements. These forward-looking statements are based largely on IGC Pharma's expectations and are subject to several risks and uncertainties, certain of which are beyond IGC Pharma's control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, the Company's failure or inability to commercialize one or more of the Company's products or technologies, including the products or formulations described in this release, or failure to obtain regulatory approval for the products or formulations, where required, or government regulations affecting AI or the AI algorithms not working as intended or producing accurate predictions; general economic conditions that are less favorable than expected; the FDA's general position regarding cannabis- and hemp-based products; and other factors, many of which are discussed in IGC Pharma's U.S. Securities and Exchange Commission ("SEC") filings. IGC incorporates by reference its Annual Report on Form 10-K filed with the SEC on June 27, 2025, as if fully incorporated and restated herein. Considering these risks and uncertainties, there can be no assurance that the forward-looking information contained in this release will occur. IGC Pharma, Inc. assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.
Contact Information:
Rosalyn Christian / John Nesbett
IMS Investor Relations
igc@imsinvestorrelations.com
(203) 972-9200
SOURCE: IGC Pharma, Inc.
View the original press release on ACCESS Newswire
FAQ
What price target did Ascendiant set for IGC on December 10, 2025?
Did Ascendiant link IGC's stock outlook to clinical data timelines for 2025/26?
Where can investors get the Ascendiant coverage report on IGC (IGC)?
Does IGC endorse the Ascendiant analyst report or its conclusions?
Was the Ascendiant report issued after IGC reported Q2 results?
How might Ascendiant's revised $4.75 target affect IGC shareholders near term?
